Bevacizumab biosimilar(Guilin Sanjin)

贝伐珠单抗生物类似药（桂林三金）

Report date: 2022/03/15 18:01:26

Base Information

Drug NameBevacizumab biosimilar(Guilin Sanjin)

Drug Alias NameRecombinant anti-VEGF humanized monoclonal antibody (Guilin Sanjin )重组抗VEGF人源化单克隆抗体注射液（桂林三金）贝伐珠单抗生物仿制药（桂林三金）贝伐单抗生物仿制药（桂林三金）贝伐赛珠单抗生物仿制药（桂林三金） +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuilin Sanjin Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuilin Sanjin Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A